Esperion Therapeutics (ESPR) Earnings Date, Estimates & Call Transcripts

$2.43

0.00 (0.00%)

(As of 07/26/2024 ET)

Upcoming Earnings Date: Aug. 12
Before Market Opens
Confirmed
Actual EPS (May. 7): $0.34 Beat By $0.42
Consensus EPS (May. 7): -$0.08

ESPR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ESPR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Crypto 101 Media

Brace Yourself: Experts calling for Bitcoin to hit $100k

For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.

Click here to get The Crypto Bull Run Millionaire Blueprint now.

Esperion Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	3	($0.38)	($0.24)	($0.29)
Q2 2024	3	($0.23)	($0.10)	($0.16)
Q3 2024	3	($0.20)	($0.07)	($0.15)
Q4 2024	3	($0.20)	$0.12	($0.08)
FY 2024	12	($1.01)	($0.29)	($0.68)
Q1 2025	1	($0.11)	($0.11)	($0.11)
Q2 2025	1	($0.01)	($0.01)	($0.01)
Q3 2025	1	$0.00	$0.00	$0.00
Q4 2025	1	$0.10	$0.10	$0.10
FY 2025	4	($0.02)	($0.02)	($0.02)
Q1 2026	1	$0.02	$0.02	$0.02

ESPR Earnings Date and Information

Esperion Therapeutics last announced its quarterly earnings data on May 7th, 2024. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.42. The company had revenue of $137.74 million for the quarter, compared to analysts' expectations of $53.11 million. Esperion Therapeutics has generated ($0.99) earnings per share over the last year (($0.99) diluted earnings per share). Earnings for Esperion Therapeutics are expected to grow by 966.67% in the coming year, from $0.03 to $0.32 per share. Esperion Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, August 12th, 2024. Esperion Therapeutics will be holding an earnings conference call on Tuesday, August 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call..

Esperion Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
8/12/2024 (Confirmed)	-	-	-	-	-	-	-
5/7/2024	Q1 2024	($0.08)	$0.34	+$0.42	$0.34	$53.11 million	$137.74 million
2/27/2024	Q4 2023	($0.53)	($0.50)	+$0.03	($0.50)	$26.84 million	$32.25 million
11/7/2023	Q3 2023	($0.42)	($0.37)	+$0.05	($0.37)	$30.84 million	$33.97 million
8/1/2023	Q2 2023	($0.61)	($0.46)	+$0.15	($0.46)	$24.64 million	$25.79 million
5/9/2023	Q1 2023	($0.65)	($0.79)	($0.14)	($0.79)	$21.97 million	$24.30 million
2/21/2023	Q4 2022	($0.87)	($0.76)	+$0.11	($0.76)	$20.60 million	$18.18 million
Get the Latest News and Ratings for ESPR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/1/2022	Q3 2022	($0.93)	($0.81)	+$0.12	($0.81)	$19.83 million	$18.98 million
8/2/2022	Q2 2022	($0.95)	($1.05)	($0.10)	($1.05)	$18.62 million	$18.80 million
5/3/2022	Q1 2022	($0.96)	($0.93)	+$0.03	($0.93)	$15.41 million	$18.84 million
2/22/2022	Q4 2021	($2.32)	($1.77)	+$0.55	($1.77)	$14.48 million	$15.40 million
11/2/2021	Q3 2021	($2.86)	($2.62)	+$0.24	($2.62)	$12.31 million	$14.41 million
8/3/2021	Q2 2021	($1.82)	($1.67)	+$0.15	($1.67)	$42.16 million	$40.70 million
5/4/2021	Q1 2021	($2.08)	($3.50)	($1.42)	($3.50)	$34.28 million	$8.00 million
2/22/2021	Q4 2020	($3.76)	($3.89)	($0.13)	($3.89)	$12.52 million	$9.64 million
11/5/2020	Q3 2020	($3.52)	($3.07)	+$0.45	($3.07)	$4.04 million	$3.83 million
8/10/2020	Q2 2020	$2.13	$4.32	+$2.19	$4.32	$147.97 million	$212.24 million
5/6/2020	Q1 2020	($3.14)	($2.84)	+$0.30	($2.84)	$0.39 million	$1.80 million
2/27/2020	Q4 2019	($2.67)	($2.26)	+$0.41	($2.26)	$0.99 million	$0.98 million
11/6/2019	Q3 2019	($1.95)	($2.37)	($0.42)	($2.52)	$0.99 million	$0.98 million
8/8/2019	Q2 2019	($1.86)	($2.01)	($0.15)	($2.01)	$1.05 million	$0.98 million

Esperion Therapeutics Earnings - Frequently Asked Questions

When is Esperion Therapeutics's earnings date?: Esperion Therapeutics has confirmed that its next quarterly earnings data will be published on Monday, August 12th, 2024. Learn more on ESPR's earnings history.
Did Esperion Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Esperion Therapeutics (NASDAQ:ESPR) reported $0.34 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.08) by $0.42. Learn more on analysts' earnings estimate vs. ESPR's actual earnings.
How much revenue does Esperion Therapeutics generate each year?: Esperion Therapeutics (NASDAQ:ESPR) has a recorded annual revenue of $116.33 million.
How much profit does Esperion Therapeutics generate each year?: Esperion Therapeutics (NASDAQ:ESPR) has a recorded net income of -$209.25 million. ESPR has generated -$0.99 earnings per share over the last four quarters.
What is Esperion Therapeutics's price-to-earnings ratio?: Esperion Therapeutics (NASDAQ:ESPR) has a forward price-to-earnings ratio of 81.00. The price/earnings-to-growth ratio is 1.51.
What is Esperion Therapeutics's EPS forecast for next year?: Esperion Therapeutics's earnings are expected to grow from $0.03 per share to $0.32 per share in the next year, which is a 966.67% increase.